Holen Sie sich die Stockscreener-App
2.05
1.99%
0.04
Handel nachbörslich:
2.05
Schlusskurs vom Vortag:
$2.01
Offen:
$2.05
24-Stunden-Volumen:
48,263
Relative Volume:
0.57
Marktkapitalisierung:
$90.31M
Einnahmen:
$18.11M
Nettoeinkommen (Verlust:
$-18.95M
KGV:
-4.6857
EPS:
-0.4375
Netto-Cashflow:
-
1W Leistung:
+3.54%
1M Leistung:
+7.33%
6M Leistung:
-31.89%
1J Leistung:
-37.50%
1-Tages-Spanne:
$2.00
$2.06
1-Wochen-Bereich:
$1.96
$2.27
52-Wochen-Spanne:
$1.64
$3.5807
Adagene Inc Adr Stock (ADAG) Company Profile
Vergleichen Sie ADAG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
2.05 | 90.31M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Eingeleitet | China Renaissance | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
Adagene Inc. to Initiate Phase 2 Trial of ADG126 for Colorectal Cancer with Enrollment Starting in April 2025 - Nasdaq
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire
Could This New Colorectal Cancer Trial Change Pre-Surgery Treatment? Adagene Tests ADG126 - StockTitan
Head to Head Analysis: Rafael (NYSE:RFL) versus Adagene (NASDAQ:ADAG) - Defense World
Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 50.2% - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World
Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat
Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat
Adagene (NASDAQ:ADAG) Cut to “Equal Weight” at Morgan Stanley - Defense World
FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat
HC Wainwright Estimates Adagene FY2029 Earnings - MarketBeat
Morgan Stanley Downgrades Adagene to Equal Weight From Overweight -January 31, 2025 at 07:57 am EST - Marketscreener.com
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Adagene Reports Promising Results in Colorectal Cancer Study - TipRanks
FY2029 Earnings Forecast for Adagene Issued By HC Wainwright - Defense World
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene (NASDAQ:ADAG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright lifts Adagene stock target to $8 on ASCO data - Investing.com
Adagene reports positive colorectal cancer trial results - Investing.com India
ADAGAdagene Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - The Manila Times
Adagene's Muzastotug Shows 33% Response Rate in Colorectal Cancer Trial - StockTitan
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Adagene to present new ADG126 clinical data at ASCO-GI By Investing.com - Investing.com Australia
Adagene to Announce Updated Data from Phase 1b/2 Study of - GlobeNewswire
Adagene to Present New ADG126-KEYTRUDA Combo Data for Colorectal Cancer at ASCO GI Symposium - StockTitan
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024, Business Wires News - AsiaOne
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 - Wahanariau
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 - GlobeNewswire
Adagene Hosts Expert Panel on Breakthrough Cancer Treatment ADG126 for Colorectal Cancer - StockTitan
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Short Interest in Adagene Inc. (NASDAQ:ADAG) Increases By 88.2% - MarketBeat
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Fmr LLC Has $2.84 Million Stock Holdings in Adagene Inc. (NASDAQ:ADAG) - Defense World
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance
Short Interest in Adagene Inc. (NASDAQ:ADAG) Drops By 87.8% - Defense World
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Anheuser-Busch InBev S.A. ADR falls Monday, underperforms market - MSN
Algorae Pharmaceuticals Streamlines Operations with OTCQB Exit - MSN
Finanzdaten der Adagene Inc Adr-Aktie (ADAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.45%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):